Voyager Therapeutics, Inc.VYGRNASDAQ
Loading
Year-over-year research & development expense growth
Latest
0.24%
↓ 95% vs avg
Percentile
P41
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
5.04%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 0.24% |
| Q3 2025 | 14.48% |
| Q2 2025 | -0.62% |
| Q1 2025 | -11.40% |
| Q4 2024 | 17.66% |
| Q3 2024 | -12.22% |
| Q2 2024 | 33.04% |
| Q1 2024 | 6.04% |
| Q4 2023 | -5.58% |
| Q3 2023 | 17.64% |
| Q2 2023 | 18.40% |
| Q1 2023 | 27.61% |
| Q4 2022 | -24.75% |
| Q3 2022 | 54.36% |
| Q2 2022 | -12.70% |
| Q1 2022 | 2.35% |
| Q4 2021 | -21.74% |
| Q3 2021 | -8.16% |
| Q2 2021 | -12.71% |
| Q1 2021 | 1.59% |
| Q4 2020 | -12.15% |
| Q3 2020 | -14.90% |
| Q2 2020 | -8.89% |
| Q1 2020 | -11.65% |
| Q4 2019 | 22.75% |
| Q3 2019 | 4.20% |
| Q2 2019 | 15.08% |
| Q1 2019 | 46.81% |
| Q4 2018 | 1.70% |
| Q3 2018 | 0.76% |
| Q2 2018 | 11.14% |
| Q1 2018 | 11.45% |
| Q4 2017 | -31.87% |
| Q3 2017 | 27.85% |
| Q2 2017 | 8.73% |
| Q1 2017 | 10.60% |
| Q4 2016 | 23.42% |
| Q3 2016 | -1.67% |
| Q2 2016 | 20.06% |
| Q1 2016 | -5.29% |